Objective: In Belize, the main vector for Trypanosoma cruzi, the agent of Chagas disease, is Triatoma dimidiata, but transmission cycles and the risk for human infection are unclear. Therefore, the aim of this study was to identify T. dimidiata blood feeding sources and its parasite and microbial diversity, in order to reconstruct T.
View Article and Find Full Text PDFVector Borne Zoonotic Dis
February 2009
Chagas disease is a major public health problem from South America to Mexico, with approximately 10 million infected people. Chagas disease is known to occur in Belize, but little is known about the prevalence of Trypansoma cruzi infection in the Belizean population or the Chagas vector in this region. An entomologic survey of triatomines in the central and southern region of Belize was thus performed.
View Article and Find Full Text PDFBraz J Infect Dis
December 2007
The combination of pegylated interferon (PEG-INF) and ribavirin is currently the best treatment for chronic hepatitis C, providing a sustained virological response (SVR) in 54%-63% of patients. In patients infected with hepatitis C virus (HCV) genotype 1, the SVR rate is 42%-52%. To evaluate the treatment efficacy of this drug combination, we conducted an open, prospective study of 58 consecutive treatment-naïve patients infected with HCV genotype 1 and treated at a university hospital, comparing those presenting an SVR (SVRs), nonresponders (NRs), and relapsers (RELs).
View Article and Find Full Text PDFAntimicrob Agents Chemother
November 2001
Staphylococcus epidermidis is a major cause of infections associated with indwelling medical devices. Biofilm production is an important virulence attribute in the pathogenesis of device-related infections. Therefore, elimination of these biofilms is an ideal treatment.
View Article and Find Full Text PDFFish Shellfish Immunol
July 2000
An in vitro phagocytosis assay was developed for hybrid striped bass (Morone saxatilis x Morone chrysops), using cells collected from the peritoneal cavity of this fish. The findings indicated that: (1) 10 days following a single intraperitoneal injection (1 ml) of Freund's incomplete adjuvant (FIA) was an appropriate time for collecting suitable working concentrations (5.3+/-4.
View Article and Find Full Text PDF